VCNX - Multiplikator P/S Vaccinex, Inc

Vaccinex, Inc. (VCNX) is a recognized expert in developing antibodies against oncology and brain degeneration. Historical P/S dynamics demonstrate volatility driven by the unique SEMA4D platform for combating Alzheimer's disease, yet constrained by the risk of cash depletion. The value is currently held at 9.30, allowing for a real-time assessment of the business's market value relative to its revenue volumes.

VCNX (Vaccinex, Inc) riwayat Rasio rega marang pendapatan saka 04.07.2022 nganti 21.12.2024

Vaccinex, Inc (VCNX) - rincian metrik lan laporan keuangan

- rega pasar lan target rega analis:

Kutipan saham vaccinex.com|VCNX - Target konsensus

- statistik kapitalisasi pasar:

Kapitalisasi pasar Vaccinex, Inc|VCNX - Nilai Total Perusahaan

- data ekuitas miturut neraca:

Ekuitas saben Saham Vaccinex|VCNX - Nilai Buku Perusahaan|Koefisien Nilai Pasar marang Nilai Buku vaccinex.com|VCNX - Gunggung Aset Perusahaan

- indikator beban kredit lan likuiditas emiten:

- indikator pendapatan resik lan kelipatan nilai:

VCNX - Bathi resik|Proyeksi bathi mangsa ngarep Vaccinex, Inc.|VCNX - Rasio rega marang bathi|Rasio rega marang bathi sing dikarepake Vaccinex Inc.|VCNX - Pangali rega marang bathi tumrap wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Vaccinex, Inc|VCNX - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Vaccinex|VCNX - Bathi resik saben saham (EPS TTM)|Wutah bathi EPS kuartalan vaccinex.com|VCNX - Wutah bathi ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Vaccinex, Inc.

- data total pendapatan lan volume dodolan:

VCNX - Pendapatan lan volume dodolan|Volume dodolan mangsa ngarep perusahaan vaccinex.com|VCNX - Multiplikator P/S|Rasio kapitalisasi marang dodolan sing dikarepake Vaccinex, Inc

Analisis umum perusahaan:vaccinex.com, VCNX

For the biotech leader Vaccinex, Inc. (VCNX), which is developing the innovative SEMA4D antibody platform, the company's P/S ratio serves as an indicator of market expectations regarding the commercialization of its R&D potential. This ratio is calculated as the relationship between market capitalization and annual sales volume, allowing investors to determine the cost per unit of revenue and assess the premium paid for the issuer's future technological success within the neurodegenerative disease sector.

Perusahaan pesaing

Kapitalisasi marang pendapatan immunitybio.com IBRX|Immunocore - Kapitalisasi marang pendapatan|Multiplikator P/S Janux Therapeutics Inc JANX|RCUS - Rasio rega marang pendapatan|ZYME (Zymeworks Biopharmaceuticals) - Rasio kapitalisasi marang pendapatan|Tango Therapeutics (TNGX) - Rasio rega marang pendapatan|Rega marang dodolan iovance.com (IOVA)|Kapitalisasi marang pendapatan IMTX|XNCR - Multiplikator rega marang pendapatan|Kapitalisasi marang pendapatan CMPX (Compass Bio)|Kapitalisasi marang volume dodolan REPL|Multiplikator P/S LYEL (Lyell Immunopharma)|Rasio kapitalisasi pasar marang pendapatan IPHA|Pyxis - Multiplikator P/S|Rega marang dodolan Compugen Ltd.|IO Biotech Corp (IOBT) - Rasio rega marang pendapatan|Sutro Biopharma, Inc - Rasio kapitalisasi pasar marang pendapatan|INKT (MiNK Therapeutics, Inc.) - Multiplikator P/S|Multiplikator P/S Werewolf|Rasio rega marang pendapatan Immix Biopharma, Inc. (IMMX)|ALXO: Rasio rega marang dodolan|Cue Biopharma, Inc. - Kapitalisasi marang pendapatan|PDS Biotech (PDSB) - Rega marang dodolan|SONN: Kapitalisasi marang pendapatan|MAIA: Rasio rega marang pendapatan|LIMN: Multiplikator P/S|LAVA Therapeutics (LVTX) - Multiplikator P/S|NXTC (NextCure Corp) - Multiplikator P/S|Kapitalisasi marang pendapatan Leap Tx (LPTX)|Multiplikator P/S INTS|Kapitalisasi marang pendapatan senseibio.com SNSE|Multiplikator P/S TOVX (Theriva Biologics)|Koefisien rega marang pendapatan Gritstone bio Inc. (GRTS)|KA - Rasio rega marang pendapatan|NEXI (NexImmune Corporation) - Rasio kapitalisasi marang pendapatan|TSBX: Multiplikator P/S|Rega marang dodolan harpoontx.com (HARP)